
SYMBIOTEC
SYMBIOTEC PHARMALAB LIMITED
- IPO Status
- Closed
- Open Date
- 24 Aug 2026
- Close Date
- 27 Aug 2026
IPO Details
- Min. Investment
- ₹14,820
- Price Band
- ₹938 - ₹988
- Lot Size
- 15 shares
- Issue Size
- ₹1,757 Cr
- Face Value
- 2
- IPO Doc
- —
Schedule
- IPO open24 Aug 2026
- IPO close date27 Aug 2026
- Allotment date28 Aug 2026
- Funds unblock or debit28 Aug 2026
- Listing date1 Sep 2026
Financial Performance
- Revenue
- Profit
Stocks similar to SYMBIOTEC
- Concord Biotech Limited
- Divi's Laboratories Limited
- Cohance Lifesciences Limited
- Laurus Labs Limited
FAQs
SYMBIOTEC PHARMALAB LIMITED IPO is a Mainboard IPO aggregating up to ₹1,757 Cr, with equity shares of face value ₹2 each. The shares are proposed to be listed on NSE and BSE.
The SYMBIOTEC PHARMALAB LIMITED IPO opened on 24 Aug 2026 and closed on 27 Aug 2026. IPO Period: 24 Aug 2026 – 27 Aug 2026.
The price band for the SYMBIOTEC PHARMALAB LIMITED IPO is ₹938 to ₹988 per share. Investors can bid within the specified price band, subject to the applicable IPO rules.
The minimum lot size is 15 shares. At the upper price band of ₹988, the minimum investment required is ₹14,820.
Particular Details Lot Size 15 shares Price Band ₹938 – ₹988 Minimum Investment ₹14,820 Maximum Retail Lots 13 Here is the timeline for the SYMBIOTEC PHARMALAB LIMITED IPO:
IPO Event Date IPO Opens 24 Aug 2026 IPO Closes 27 Aug 2026 UPI Mandate Deadline 27 Aug 2026, 5:00 PM Basis of Allotment 28 Aug 2026 Refund Initiation 28 Aug 2026 Shares Credited 31 Aug 2026 Listing Date 1 Sep 2026 The basis of allotment for the SYMBIOTEC PHARMALAB LIMITED IPO is expected to be finalised on 28 Aug 2026. Investors can check their allotment status through the registrar or relevant stock exchange website using their application details. Registrar: Link Intime.
The equity shares of SYMBIOTEC PHARMALAB LIMITED are proposed to be listed on NSE and BSE. Proposed Listing Date: 1 Sep 2026.
The key financial performance of SYMBIOTEC PHARMALAB LIMITED is:
Financial Year Revenue Profit FY24 ₹716.25 Cr ₹100.06 Cr FY25 ₹751.55 Cr ₹96.78 Cr FY26 ₹869.15 Cr ₹109.88 Cr Revenue CAGR: 10.2% | Profit CAGR: 4.8%. Figures are as disclosed in the company's offer documents.


